Zentalis Pharmaceuticals share price logo

Zentalis Pharmaceuticals

NASDAQ: ZNTL

Small Cap

$3.99

-0.12

(-2.92%)

as on

Zentalis Pharmaceuticals Stock Performance

as on September 5, 2026 at 6:59 am IST

  • Day's Low

    Day's High

    $3.92
    $4.19
    downward going graph

    1.75%

    Downside

    5.01%

    Upside

    downward going graph
  • 52 Week's Low

    52 Week's High

    $1.21
    $6.95
    downward going graph

    69.62%

    Downside

    74.19%

    Upside

    downward going graph

Zentalis Pharmaceuticals share price movements today

Previous Close
$4.11
Open
$4.05
Volume
1.1M
Market Cap
$356.9M
Day's Low - High
$3.92 - $4.19
52 Week Low - High
$1.21 - $6.95

Zentalis Pharmaceuticals Historical Returns

1 Month Return
-15.78 %
3 Month Return
+ 6.2 %
1 Year Return
+ 132.2 %
3 Year Return
-84.86 %
5 Year Return
-93.8 %

Zentalis Pharmaceuticals Stock Fundamentals & Key Indicators

Check Zentalis Pharmaceuticals market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$356.9M

EPS (TTM)

-2.1129

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

0

PEG Ratio

0

EBITDA

-149.8M

Revenue (TTM)

26.9M

Profit Margin

0.00%

Return On Equity TTM

-66.75%

Zentalis Pharmaceuticals vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Zentalis Pharmaceuticals with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %Dividend Yield %
BUY$356.9M-93.8%NA0.00%NA
BUY$44.6B614.61%NA0.00%NA
BUY$141.1B181.73%32.2186.04%NA
BUY$60.2B-64.27%-18.66-12.57%NA
BUY$84.8B24.12%20.1484.86%0.44%

Stock Returns calculator for Zentalis Pharmaceuticals Stock including INR - Dollar returns

The Zentalis Pharmaceuticals stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

Zentalis Pharmaceuticals investment value today

Current value as on today

₹2,41,506

Returns

₹1,41,506

(+141.51%)

Returns from Zentalis Pharmaceuticals Stock

₹1,25,424 (+125.42%)

Dollar Impact

₹16,083 (+16.08%)

Analyst Recommendation on Zentalis Pharmaceuticals Stock

Based on 6 analysts

BUY

83.33%

Buy

16.67%

Hold

0.00%

Sell

Based on 6 analysts, 83.33333333333334% of analysts recommend a 'BUY' rating for Zentalis Pharmaceuticals. Average target price of $6.89

Zentalis Pharmaceuticals Share Price Target

Get share price movements and forecasts by analysts on Zentalis Pharmaceuticals.

What analysts predicted

42.09%UPSIDE

Target Price

$6.89

Current Price

$3.99

Analyzed by

6 Analysts

Target

$6.89

Zentalis Pharmaceuticals target price $6.89, a slight upside of 42.09% compared to current price of $3.99. According to 6 analysts rating.

Indian Investors' Interest in Zentalis Pharmaceuticals Stock

Search interest for Zentalis Pharmaceuticals Stock has decreased by -4% in the last 30 days, reflecting a downward trend in search activity.

Time period: to

Change:-4% versus previous 30 day period

Zentalis Pharmaceuticals Quarterly Profit & Loss

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Total Revenue
40
-
-
26
-
-
-
-
-
-
Gross Profit
40
0
0
26
0
0
-
0
0
-
Operating Income
-24
-65
-51
-49
-45
-36
-33
-37
-37
-82
EBITDA
10
-87
-39
-45
-37
-34
-26
-34
-35
-77
Interest Expense
-
-
-
-
-
-
-
-
-
-
Depreciation
0
0
0
0
0
0
0
0
0
0
Income Before Tax
10
-88
-40
-47
-48
-26
-26
-34
-35
-77
Income Tax Expense
0
0
0
0
-
-
-
0
0
0
Net Income
10
-88
-40
-47
-48
-26
-26
-35
-35
-77
Net Profit Margin
24.82%
0.00%
0.00%
-176.71%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%

Zentalis Pharmaceuticals Annual Profit & Loss

All numbers in Millions USD

Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
0
-
-
-
-
-
67
-
Gross Profit
0
0
0
0
-1
-1
67
0
Operating Income
-23
-46
-118
-216
-227
-299
-191
-152
EBITDA
-23
-46
-118
-207
-233
-247
-186
-144
Interest Expense
-
1
2
110
2
-
-
-
Depreciation
0
0
0
0
1
1
1
0
Income Before Tax
-23
-46
-118
-166
-237
-292
-165
-136
Income Tax Expense
0
0
0
0
0
0
0
0
Net Income
-21
-45
-117
-158
-236
-292
-165
-137
Net Profit Margin
-150478.57%
0.00%
0.00%
0.00%
0.00%
0.00%
-245.96%
0.00%

Zentalis Pharmaceuticals Quarterly Cash Flow

All numbers in Millions USD

Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Net Income
-88
-40
-47
-48
-26
-26
-35
-35
-77
Operating Cash Flow
-35
-44
-39
-32
-34
-26
-30
-32
-70
Investing Cash Flow
34
48
32
40
30
28
32
30
60
Financing Cash Flow
0
0
-
0
-
0
-4
-1
-1
Change in Cash
0
4
-7
8
-4
1
-3
-4
-11

Zentalis Pharmaceuticals Annual Cash Flow

All numbers in Millions USD

Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
-46
-118
-166
-237
-292
-165
-137
Operating Cash Flow
-39
-86
-154
-163
-207
-170
-125
Investing Cash Flow
0
-284
-18
-114
-44
176
131
Financing Cash Flow
81
360
178
261
237
0
-4
Change in Cash
42
-11
6
-16
-14
5
2

Mutual Funds that own Zentalis Pharmaceuticals Stock

Check out the Mutual Funds with significant holdings in Zentalis Pharmaceuticals.

Funds
Holdings
Shares Held
VANGUARD INDEX FUNDS
2.364146%
2238183
PRIMECAP Odyssey Funds
0.714467%
676400
Fidelity Concord Street Trust
0.501796%
475060
Franklin Strategic Series
0.464804%
440039
VANGUARD HORIZON FUNDS
0.22111%
209330

Global Institutional Holdings in Zentalis Pharmaceuticals

Funds
Holdings
Christopher J. Burke
14.75%
Vanguard
3.76%
iShares
1.98%
Theofanis Kolokotrones
1.01%
Fidelity
0.61%

Insights on Zentalis Pharmaceuticals

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 7 days, ZNTL stock has moved up by 8.2%

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, Revolution Medicines, Inc. Common Stock has given 32.3% return, outperforming this stock by 117.2%

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Moderna, Inc. Common Stock has given 513.1% return, outperforming this stock by 380.9%

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers in the United States. It develops azenosertib, which is in a Phase 3 clinical trial for the treatment of ovarian cancer and other tumor types. The company also develops ZN-c3-001, a phase 1 study that evaluated azenosertib monotherapy in solid tumors; and MAMMOTH (ZN-c3-006) is a Phase 1/2 clinical trial of azenosertib in patients with PARP-inhibitor resistant ovarian cancer. It has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC. Zentalis Pharmaceuticals, Inc. was incorporated in 2014 and is based in San Diego, California.
OrganisationZentalis Pharmaceuticals
Headquarters10275 Science Center Dr., San Diego, CA, United States, 92121
IndustryBiotechnology
CEOMs. Julie M. Eastland M.B.A.
E-voting on sharesClick here to vote

Key Management of Zentalis Pharmaceuticals

Name

Title

Ms. Julie M. Eastland M.B.A.

CEO, President & Director

Mr. James B. Bucher J.D.

Chief Legal Officer & Corporate Secretary

Dr. Ingmar Bruns M.D., Ph.D.

Chief Medical Officer

Ms. Wendy Chang

Chief People Officer

Mr. Haibo Wang

Chief Business Officer

Ms. Sarah Kelly

Senior Vice President of Commercial Strategy

Mr. Vincent A. Vultaggio

SVP of Finance & Principal Accounting Officer

Mr. Robert J. DiVasto P.E.

Chief Technical Officer

Mr. Rajesh Israni

Executive VP of Regulatory Affairs & Medical Writing

Mr. Henry Gu

Senior VP & Head of Intellectual Property

FAQs

What is Zentalis Pharmaceuticals share price today?

Zentalis Pharmaceuticals share price today is $3.99 as on at the close of the market. Zentalis Pharmaceuticals share today touched a day high of $4.19 and a low of $3.92.

What is the 52 week high and 52 week low for Zentalis Pharmaceuticals share?

Zentalis Pharmaceuticals share touched a 52 week high of $6.95 on and a 52 week low of $1.21 on . Zentalis Pharmaceuticals stock price today i.e. is closed at $3.99,which is 42.59% down from its 52 week high and 229.21% up from its 52 week low.

What is Zentalis Pharmaceuticals's market capitalisation today?

Zentalis Pharmaceuticals market capitalisation is $0.00T as on .

How to invest in Zentalis Pharmaceuticals Stock (ZNTL) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Zentalis Pharmaceuticals on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Zentalis Pharmaceuticals Shares that will get you 0.3759 shares as per Zentalis Pharmaceuticals share price of $3.99 per share as on September 5, 2026 at 1:29 am IST.

What is the minimum amount required to buy Zentalis Pharmaceuticals Stock (ZNTL) from India?

Indian investors can start investing in Zentalis Pharmaceuticals (ZNTL) shares with as little as ₹94.485 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹944.85 in Zentalis Pharmaceuticals stock (as per the Rupee-Dollar exchange rate as on ). Based on Zentalis Pharmaceuticals share’s latest price of $3.99 as on September 5, 2026 at 1:29 am IST, you will get 2.5063 shares of Zentalis Pharmaceuticals. Learn more about fractional shares .

What are the returns that Zentalis Pharmaceuticals has given to Indian investors in the last 5 years?

Zentalis Pharmaceuticals stock has given -93.8% share price returns and 29.94% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?